- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | VITA LIFE SCIENCES LIMITED: Update - Notification of buy-back - VLS | - | ASX | ||
| So | VITA LIFE SCIENCES LIMITED: AGM Date and Closing Date for Directors' Nomination | - | ASX | ||
| 27.03. | VITA LIFE SCIENCES LIMITED: Update - Notification of buy-back - VLS | - | ASX | ||
| 26.03. | VITA LIFE SCIENCES LIMITED: App 4G Corporate Governance Statement | 1 | ASX | ||
| 26.03. | VITA LIFE SCIENCES LIMITED: Annual Report to shareholders | 2 | ASX | ||
| 24.03. | VITA LIFE SCIENCES LIMITED: Notification of cessation of securities - VLS | - | ASX | ||
| VITA LIFE SCIENCES Aktie jetzt für 0€ handeln | |||||
| 19.03. | VITA LIFE SCIENCES LIMITED: Update - Notification of buy-back - VLS | - | ASX | ||
| 17.03. | VITA LIFE SCIENCES LIMITED: Notification of cessation of securities - VLS | - | ASX | ||
| 15.03. | VITA LIFE SCIENCES LIMITED: Update - Notification of buy-back - VLS | - | ASX | ||
| 12.03. | VITA LIFE SCIENCES LIMITED: Update - Notification of buy-back - VLS | - | ASX | ||
| 11.03. | VITA LIFE SCIENCES LIMITED: Update - Notification of buy-back - VLS | - | ASX | ||
| 09.03. | VITA LIFE SCIENCES LIMITED: Update - Notification of buy-back - VLS | - | ASX | ||
| 08.03. | VITA LIFE SCIENCES LIMITED: Update - Notification of buy-back - VLS | - | ASX | ||
| 05.03. | VITA LIFE SCIENCES LIMITED: Notification of cessation of securities - VLS | 1 | ASX | ||
| 26.02. | VITA LIFE SCIENCES LIMITED: Update - Notification of buy-back - VLS | - | ASX | ||
| 25.02. | VITA LIFE SCIENCES LIMITED: Update - Notification of buy-back - VLS | - | ASX | ||
| 24.02. | VITA LIFE SCIENCES LIMITED: Update - Notification of buy-back - VLS | - | ASX | ||
| 16.02. | VITA LIFE SCIENCES LIMITED: Dividend/Distribution - VLS | 2 | ASX | ||
| 16.02. | VITA LIFE SCIENCES LIMITED: Preliminary Final Report | 1 | ASX | ||
| 19.12.25 | VITA LIFE SCIENCES LIMITED: Notification of cessation of securities - VLS | - | ASX |
1 2 3 Weiter >>
45 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| GREEN THUMB INDUSTRIES | 5,780 | -2,61 % | RYTHM, Inc. Announces Amendments to License Agreements with Green Thumb Industries | ROLLING MEADOWS, Ill., April 01, 2026 (GLOBE NEWSWIRE) -- RYTHM, Inc. (Nasdaq: RYM) ("RYTHM" or the "Company"), America's THC Company, today announced amendments to its existing trademark and recipe... ► Artikel lesen | |
| ALNYLAM PHARMACEUTICALS | 283,00 | +2,35 % | Alnylam stellt positive Daten zu Herz-Kreislauf-Portfolio auf ACC-Konferenz vor | ||
| NEKTAR THERAPEUTICS | 66,00 | -1,49 % | Nektar Therapeutics: Data from Phase 2b REZOLVE-AD and REZOLVE-AA Studies of Rezpegaldesleukin Presented at 2026 American Academy of Dermatology Annual Meeting | Rezpegaldesleukin demonstrates statistically significant improvement in mean percent EASI improvement across both moderate and severe atopic dermatitis patients
Rezpegaldesleukin... ► Artikel lesen | |
| FILANA THERAPEUTICS | 1,444 | -4,02 % | Cassava Sciences Announces Name Change to Filana Therapeutics, Inc. | New corporate identity reflects the Company's mission to develop novel medicines to modulate filamin A and address unmet needs in treating TSC-related epilepsy Filana Therapeutics to begin trading... ► Artikel lesen | |
| ADASTRA | 0,105 | 0,00 % | Adastra Holdings Ltd.: Adastra Holdings Announces Agreement to Sell Assets and Resignation of Director | Langley, British Columbia--(Newsfile Corp. - March 2, 2026) - Adastra Holdings Ltd. (CSE: XTRX) (FSE: D2E0) ("Adastra" or the "Company") announces that Adastra Labs Inc. ("Adastra Labs"), a wholly-owned... ► Artikel lesen | |
| SELLAS LIFE SCIENCES | 3,520 | -1,81 % | SELLAS Life Sciences (SLS) to Present SLS009 Data at AACR 2026 | ||
| CATALYST PHARMACEUTICALS | 21,490 | +0,37 % | Catalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals Reports Record Fourth Quarter and Record Full Year 2025 Financial Results and Provides 2026 Financial Guidance | Full Year 2025 Total Revenues of $589.0 Million, Representing 19.8% Year-Over-Year Growth and Marking Another Year of Record Total Revenues Q4 2025 Total Revenues of $152.6 Million, Fueled by 18.3%... ► Artikel lesen | |
| ACADIA PHARMACEUTICALS | 18,910 | -1,74 % | Acadia Pharmaceuticals Inc.: Acadia Pharmaceuticals Announces Plan to Request Re-Examination Following Negative CHMP Opinion for Trofinetide for the Treatment of Rett Syndrome | Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) informed the company it has formally... ► Artikel lesen | |
| MOLECULE HOLDINGS | 0,001 | 0,00 % | Molecule Holdings Inc. Provides Corporate Update | ||
| NUMINUS WELLNESS | 0,027 | -100,00 % | Numinus Wellness Inc.: Numinus Wellness Provides Update Regarding Listing Status | Vancouver, British Columbia--(Newsfile Corp. - March 24, 2026) - Numinus Wellness Inc. (TSX: NUMI) (OTC Pink: NUMIF) ("Numinus" or the "Company"), a mental health care company focused on innovative... ► Artikel lesen | |
| ANI PHARMACEUTICALS | 66,50 | +3,10 % | ANIP Stock Outlook: Cortrophin Growth vs. Retina Reset | ||
| ZELIRA THERAPEUTICS | 0,300 | 0,00 % | XFRA G1G: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILZELIRA THERAPEUTICS... ► Artikel lesen | |
| SOLIGENIX | 1,140 | 0,00 % | SOLIGENIX, INC.: Positive Clinical Results from HyBryte Comparative Study Evaluating HyBryte Against Valchlor in the Treatment of Cutaneous T-Cell Lymphoma Published in Oncology and Therapy | HyBryte demonstrates more rapid and robust treatment response compared toValchlor® during 12-week treatment course PRINCETON, N.J., April 2, 2026 /PRNewswire/ -- Soligenix, Inc. (Nasdaq:... ► Artikel lesen | |
| OPUS GENETICS | 3,870 | -1,78 % | Opus Genetics, Inc.: Opus Genetics Announces Financial Results for Full Year 2025 and Provides Corporate Update | - Favorable early safety and initial efficacy data from BEST1 program highlighted at premier gathering of global retinal experts with additional data expected mid-year 2026 - - Reauthorization of... ► Artikel lesen | |
| SAVARA | 4,780 | -0,42 % | Savara Inc.: Savara Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) for MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) | -- EMA Review of MOLBREEVI MAA Has Now Initiated, Decision Expected in Q1 2027 -- -- MOLBREEVI Biologics License Application (BLA) is Currently Under Priority Review with the U.S. Food and Drug... ► Artikel lesen |
Das Unternehmen VITA LIFE SCIENCES LIMITED kann der Branche Pharma zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu VITA LIFE SCIENCES LIMITED finden Sie auf Wallstreet Online.